1. Pink Sheet
  2. >>Biosimilars & Generics

For Generics, A Victory Lap – And A Warning – On Drug Shortages

 
• By Nielsen Hobbs

Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

AAM’S JONATHAN KIMBALL, LUPIN’S ALOK SONIG, MAYNE PHARMA’S HEM PANDYA, AND WASHINGTON UNIVERSITY’S ANTHONY SARDELLA DISCUSS WHAT WENT RIGHT WITH THE GENERIC INDUSTRY’S COVID RESPONSE.
AAM’S JONATHAN KIMBALL, LUPIN’S ALOK SONIG, MAYNE PHARMA’S HEM PANDYA, AND WASHINGTON UNIVERSITY’S ANTHONY SARDELLA DISCUSS WHAT WENT RIGHT WITH THE GENERIC INDUSTRY’S COVID RESPONSE. • Source: Nielsen Hobbs

ORLANDO, Fla.—The Association of Accessible Medicines’ annual meeting is back in person, and among the reminisces at the event was a 15 February panel that featured a fair bit of self-congratulation, albeit well deserved, about how the industry avoided a supply chain disaster at the beginning of the pandemic.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Generics

US FDA Shows Support For Generic Drug User Fee Goals Amid Cutbacks

 
• By Michael McCaughan

The FDA struck an upbeat tone during its annual Generic Drugs Forum despite an unprecedented period of cutbacks and disruptions and reiterated a desire to continue meeting user fee goals.

Beyond Tariffs: The Silver Lining Of The US Pharma Security Investigation

 
• By Jessica Merrill

An investigation by the US Secretary of Commerce into pharmaceutical imports gives industry an opportunity to comment. AAM CEO John Murphy talked to Pink Sheet's sister publication Scrip about the latest developments.

US FDA Finds ‘Significant’ Data Integrity Breaches In CRO Raptim Studies

 
• By Urtė Fultinavičiūtė

The US FDA has deemed certain in vitro bioequivalence studies conducted by CRO Raptim Research “not acceptable” and raised concerns over its in vivo study methods.

Japan Pushes Generic Industry Reforms Via New Govt Fund

 
• By Lisa Takagi

Amid ongoing generic drug supply problems, Japan's government is to set up a new fund to support corporate investments geared towards manufacturing and consolidation.

More from Conferences